SARS-CoV-2 infection in alpha1-antitrypsin deficiency.

Authors:
Schneider CV; Strnad P.

Journal:
Respir Med

Publication Year: 2021

DOI:
10.1016/j.rmed.2021.106466

PMCID:
PMC8116136

PMID:
34010739

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Respir Med

Abbreviation: Respir Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patien…
Keur N; Saridaki M; Ricaño-Ponce I and 3 more (2023) - Transparency Score: 4/6
Lung parenchymal abnormalities and outcomes in hospitalized patients with COVID 19 pneumonia: A pos…
Datta B; Prakash AK; Yaddanapudi K and 7 more (2023) - Transparency Score: 3/6
Lung ultrasound as a tool for monitoring the interstitial changes in recently hospitalised patients…
Loke TK; Earl N; Begbey ACH and 7 more (2023) - Transparency Score: 3/6
Multiple manifestations of uncontrolled asthma increase the risk of severe COVID-19.
Selberg S; Karlsson Sundbaum J; Konradsen JR and 4 more (2023) - Transparency Score: 3/6
Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and ou…
Ragnoli B; Cena T; Radaeli A and 5 more (2023) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of competing interest Dr. Strnad reports receiving grant support and lecture fees from 10.13039/501100016387Grifols and 10.13039/100008322CSL Behring, grant support and advisory board fees from 10.13039/100014931Arrowhead Pharmaceuticals, grant support from 10.13039/100011022Vertex Pharmaceuticals, advisory board fees from Dicerna Pharmaceuticals, and lecture fees from 10.13039/100006400Alnylam Pharmaceuticals."

Evidence found in paper:

"10.13039/501100016387Grifols; 10.13039/100008322CSL Behring; 10.13039/100014931Arrowhead Pharmaceuticals; 10.13039/100011022Vertex Pharmaceuticals; 10.13039/100006400Alnylam Pharmaceuticals"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025